Home
Ignyta, Inc.

Ignyta, Inc. Market Share Analysis for May 2026

breakthrough science. one moment, one day, one person at a time.

Health > Biotechnology and Pharmaceuticals

Domainignyta.com

Year Founded2011

Employees51 - 200

Annual Revenue< $1M

Ignyta, Inc.

Ignyta, Inc. (including company regionals)

ignyta.com

See more website traffic and engagement information

Total visits to Ignyta, Inc.'s top domains

Understand Ignyta, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Ignyta, Inc.'s top domains

Analyze Ignyta, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Ignyta, Inc.'s top domains

See how Ignyta, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Ignyta, Inc. top competitors by domain

Top similar sites in May 2026, ranked by their affinity

adaptivebiotech.comCompany NameAdaptive BiotechnologiesEmployees501 - 1000HQUnited States, Washington, SeattleAnnual revenue$100M - $200MTotal visits20.9KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Ignyta, Inc.

These are the website technologies, by industry, used by Ignyta, Inc. top domains

Advertising (7)

Facebook Custom Audiences

Social (5)

Instagram

Conversion & Analytics (4)

Google Analytics

Widget (4)

Twemoji

More Technologies

8

See all

News & Signals from Ignyta, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsRoche acquired Ignyta for $1.7B on Jan 1st '18.Roche acquired the rights to the kinase inhibitor via its $1.7B acquisition of Ignyta in 2018.

NewsFoundation Medicine, Inc. partners with Ignyta.Foundation Medicine teamed up with Ignyta (a trial sponsor) and Pharmatech to present a poster at ASCO in 2017 demonstrating the utility of its trial education and access program for matching patients to studies targeting rare genomic findings.

NewsRoche acquired Ignyta for $1.7B on Dec 1st '17.Partin filled a crucial role in Roche's December 2017 tender offer to acquire biotech Ignyta Inc. for $1.7 billion.